百济神州再遭美国药企诉讼，涉嫌窃取商业秘密

知产财经09-12

知产财经从海外媒体Reuters获悉，上周五，制药巨头艾伯维（AbbVie）在美国芝加哥联邦法院起诉癌症治疗研发公司百济神州（BeiGene），指控其在雇佣艾伯维的一名前长期资深科学家后，窃取商业秘密，以开发竞争性的抗癌疗法。（案号：1:24-cv-08167）诉讼的焦点是两家公司研发的癌症治疗药物——“BTK降解剂”，它可以靶向破坏B细胞生长过程中的分子。知产财经了解到，艾伯维是一家全球多元化的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2466216852?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-12 11:33","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2466216852","market":"us","top_or_hot":-1,"title":"百济神州再遭美国药企诉讼，涉嫌窃取商业秘密","media":"知产财经","content":"<div>\n<p>知产财经从海外媒体Reuters获悉，上周五，制药巨头艾伯维（AbbVie）在美国芝加哥联邦法院起诉癌症治疗研发公司百济神州（BeiGene），指控其在雇佣艾伯维的一名前长期资深科学家后，窃取商业秘密，以开发竞争性的抗癌疗法。（案号：1:24-cv-08167）诉讼的焦点是两家公司研发的癌症治疗药物——“BTK降解剂”，它可以靶向破坏B细胞生长过程中的分子。知产财经了解到，艾伯维是一家全球多元化的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912113218ab633c56&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州再遭美国药企诉讼，涉嫌窃取商业秘密</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州再遭美国药企诉讼，涉嫌窃取商业秘密\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-12 11:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912113218ab633c56&s=b><strong>知产财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>知产财经从海外媒体Reuters获悉，上周五，制药巨头艾伯维（AbbVie）在美国芝加哥联邦法院起诉癌症治疗研发公司百济神州（BeiGene），指控其在雇佣艾伯维的一名前长期资深科学家后，窃取商业秘密，以开发竞争性的抗癌疗法。（案号：1:24-cv-08167）诉讼的焦点是两家公司研发的癌症治疗药物——“BTK降解剂”，它可以靶向破坏B细胞生长过程中的分子。知产财经了解到，艾伯维是一家全球多元化的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912113218ab633c56&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0456855351.SGD","symbol_name":"JPMorgan Funds - Global Equity A (acc) SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912113218ab633c56&s=b","article_id":"2466216852","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912113218ab633c56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2466216852","pubTimestamp":1726111996,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"百济神州“引诱并鼓励”艾伯维前科学家刘华清利用其前雇主的商业秘密“推进和加速”百济神州的BTK降解剂项目。刘华清从艾伯维退休后，于2019年9月起在百济神州工作。在该诉讼中，刘华清亦被列为被告。百济神州在周一的声明中否认了艾伯维的指控，并表示“公司将在这起诉讼中坚决捍卫我们的知识产权”。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688235":"百济神州","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4566":"资本集团","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BGNE":"百济神州","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","06160":"百济神州","LU0882574055.USD":"富达全球健康医疗A ACC","BK4550":"红杉资本持仓","BK4526":"热门中概股","BK4588":"碎股","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4505":"高瓴资本持仓","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","BK4581":"高盛持仓","BK4504":"桥水持仓","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4548":"巴美列捷福持仓","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","ABBV":"艾伯维公司","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4139":"生物科技","LU0234572021.USD":"高盛美国核心股票组合Acc"},"translate_title":"BeiGene was sued by a US pharmaceutical company again, allegedly stealing trade secrets","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":0.9,"BGNE":1,"ABBV":0.9,"06160":0.9},"content_text":"知产财经从海外媒体Reuters获悉，上周五，制药巨头艾伯维（AbbVie）在美国芝加哥联邦法院起诉癌症治疗研发公司百济神州（BeiGene），指控其在雇佣艾伯维的一名前长期资深科学家后，窃取商业秘密，以开发竞争性的抗癌疗法。（案号：1:24-cv-08167）诉讼的焦点是两家公司研发的癌症治疗药物——“BTK降解剂”，它可以靶向破坏B细胞生长过程中的分子。知产财经了解到，艾伯维是一家全球多元化的研究型生物制药公司，总部位于美国芝加哥。该公司专注于开发和销售先进的治疗药物，产品主要集中在治疗慢性自身免疫疾病、神经系统疾病、代谢性疾病等健康问题。2023年6月，艾伯维公司旗下的Pharmacyclics公司于美国特拉华州地区法院提起诉讼，指控其竞争对手百济神州公司侵犯了艾伯维公司Imbruvica在血癌治疗中使用的一项最新批准的专利。艾伯维在上周五提起的诉讼中称，公司投资了数百万美元并进行了“多年的研究”，以开发一种用于治疗与“B细胞”生长相关的某些类型的血液和骨髓癌的化合物。百济神州“引诱并鼓励”艾伯维前科学家刘华清利用其前雇主的商业秘密“推进和加速”百济神州的BTK降解剂项目。刘华清从艾伯维退休后，于2019年9月起在百济神州工作。艾伯维称，刘华清至少在艾伯维的BTK降解剂项目中工作了一年。在该诉讼中，刘华清亦被列为被告。百济神州在周一的声明中否认了艾伯维的指控，并表示“公司将在这起诉讼中坚决捍卫我们的知识产权”。百济神州的声明称，艾伯维的诉讼是“为了阻碍”百济神州竞争性BTK降解剂BGB-16673的开发。公司在艾伯维为其BTK降解剂提交专利申请之前，就已经提交了BGB-16673的专利申请。此外，美国食品药品监督管理局今年给予其药物“快速通道认定”（FTD，fast check designation），该药物正被用于一项治疗白血病和淋巴瘤的研究中。艾伯维及其律师尚未进行回应。知产财经将继续关注双方间的诉讼进程。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.0","shortVersion":"4.28.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466216852"}